Q1 2022

Filed May 11, 2022 · 10-Q · 41 days after period end · 0001193125-22-146662

Q1 2022 · 10-Q

Revenue—

Net Income

-$7.74M

no prior Q1 2021 on file

EPS, diluted—

Operating Income-$528,858—

Operating Cash Flow-$465,131—

Same quarter

no prior Q1 2021 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2022 · filed May 11, 2022 · 41 d after period end

Calidi Biotherapeutics, Inc. · CIK 1855485 · Engraved from SEC EDGAR